ACTL7A: A Potential Drug Target and Biomarker (G10881)

Target Name: ACTL7A

NCBI ID: G10881

ACTL7A

ACTL7A: A Potential Drug Target and Biomarker

Introduction

Actin-like protein 7A (ACTL7A) is a protein that is expressed in various tissues and cells, including muscle, heart, and brain. It is characterized by its ability to interact with actinin, a protein that plays a crucial role in cell signaling and cytoskeletal organization. While the exact function of ACTL7A is not yet fully understood, research has shown that it is involved in a wide range of cellular processes, including muscle contraction, cell signaling, and neurotransmission.

As a result, ACTL7A has emerged as a promising drug target and biomarker for a variety of diseases, including neurodegenerative disorders, muscle diseases, and cardiovascular disease. In this article, we will explore the potential of ACTL7A as a drug target and biomarker, as well as its potential utility in these areas.

Potential Drug Target

Actinin is a protein that plays a critical role in cell signaling and cytoskeletal organization. It is composed of two subunits, alpha-actinin and beta-actinin, which are held together by a disulfide bond. The alpha-actinin subunit contains a variety of domains , including a helix that is involved in the formation of a stable complex with other proteins, as well as a site for protein-protein interactions.

ACTL7A is characterized by its ability to interact with actinin, which allows it to play a role in the regulation of cellular processes such as muscle contraction and cell signaling. This interaction between ACTL7A and actinin suggests that ACTL7A may be a useful drug target for diseases that are characterized by the disruption of these processes.

Potential Biomarkers

ACTL7A has also been shown to be involved in a wide range of cellular processes, including muscle contraction, cell signaling, and neurotransmission. As a result, ACTL7A has the potential to serve as a biomarker for a variety of diseases.

For example, ACTL7A has been shown to be involved in the regulation of muscle contractions. Studies have shown that ACTL7A plays a role in the regulation of muscle cell contractions, and that its activity can be modulated by drugs such as resistance training and cytokines. These findings suggest that ACTL7A may be a useful biomarker for muscle diseases, such as muscle dystrophy and myopathies.

In addition, ACTL7A has also been shown to be involved in the regulation of neurotransmission. Studies have shown that ACTL7A plays a role in the regulation of neurotransmitter release from nerve axons, and that its activity can be modulated by drugs such as psychostimulants and depressants. These findings suggest that ACTL7A may be a useful biomarker for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, ACTL7A is a protein that is characterized by its ability to interact with actinin and its involvement in a wide range of cellular processes. As a result, ACTL7A has the potential to serve as a drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of ACTL7A in these processes and to develop effective treatments based on this information.

Protein Name: Actin Like 7A

Functions: May play an important role in formation and fusion of Golgi-derived vesicles during acrosome biogenesis

The "ACTL7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTL7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets